Stockadora

8-K filings / November 17, 2026

INOVIO PHARMACEUTICALS, INC.: A change of officers or directors

INOVIO PHARMACEUTICALS, INC. filed a current report (Form 8-K) with the SEC on November 17, 2026. It reports a change of officers or directors.

AI-written from the facts below

In plain English

Under Item 5.02 of Form 8-K, which covers directors and senior officers who leave or are appointed, a change to the board of directors is being disclosed. Specifically, Jeffrey Libson joins the board of directors, effective November 13, 2026.

What each sentence states
“Under Item 5.02 of Form 8-K, which covers directors and senior officers who leave or are appointed, a change to the board of directors is being disclosed.”
  • Item 5.02 of Form 8-K covers directors and senior officers who leave or are appointed.
  • Item 5.02: Jeffrey Libson joins the board of directors, effective November 13, 2026.
“Specifically, Jeffrey Libson joins the board of directors, effective November 13, 2026.”
  • Item 5.02: Jeffrey Libson joins the board of directors, effective November 13, 2026.
Written by an AI model from the facts on this page only; code and a second model checked every sentence against them.

Item 5.02

Officers and directors

  • Appointed Jeffrey Libson, DirectorEffective November 13, 2026 From the filing
    Source
    “Effective November 13, 2026, the Board of Directors (the “Board”) of Inovio Pharmaceuticals, Inc. (the “Company”) increased the size of the Board from eight to nine directors and appointed Jeffrey Libson to fill the newly created directorship.”
    Found by an AI model; the quote is checked word for word against the filing.
Not investment advice.Read the filing on SEC.gov

Facts read from the filing's own text; a fact the filing does not state clearly is left out. All documents of this filing on SEC.gov.